Almirall, S.A (0O9B) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Almirall, S.A €8.65, price €10.20, upside -15.2%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €7.11 – €13.98 · fair‑value band €6.40 – €10.91 · the €10.20 price screens above the €8.65 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.
Show more
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Stock analysis
Almirall, S.A (0O9B) currently trades at €10.20, while our model-based Fair Value estimate is €8.65, 15.2% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €9.43 per share, and 5 of the 23 models we run sit above the €10.20 price.
Bear case: the Earnings-Based group reads lowest at €3.60, and 18 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: €6.40 (bear) to €10.91 (bull), the price of €10.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Almirall, S.A reported revenue of €807M in FY2020 versus €764M in FY2016, a compound +1.4%/yr. Reported net income was €74.3M in FY2020, compounding −0.4%/yr from FY2016.
Key figures
Market cap €1.8B · P/S ratio 1.56 · EPS (TTM) €−0.2790 · Dividend yield 1.8% · Net margin 9.2% · Return on equity 4.0% · Return on assets (EBIT) 0.7% · Operating margin 13.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −15%, 0O9B screens cheaper than that median.
Fair Value models
Bear €6.40Fair Value €8.65Bull €10.91
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.6% (2016) → 11.4% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Almirall, S.A Fair Value". https://www.fairvalue-calculator.com/stock/0O9B
Frequently asked questions
Is Almirall, S.A (0O9B) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €8.65 versus a price of €10.20, about −15% upside (overvalued).
What is the fair value of 0O9B?
Our model-based fair value for Almirall, S.A is €8.65 (as of Sep 24, 2026), built from audited fundamentals. The current price: €10.20.
What is the quality score of 0O9B?
Almirall, S.A has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Almirall, S.A (0O9B)?
Our model-based price target is the fair value of €8.65 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario €6.40, optimistic scenario €10.91. It is a calculation from audited fundamentals, not an analyst target.
What is the Almirall, S.A stock forecast for 2026?
Our models put fair value at €8.65, about −15% upside versus a price of €10.20 (overvalued). Cautious scenario €6.40, optimistic scenario €10.91. The calculation is refreshed regularly with new filings.
What is the revenue of Almirall, S.A (0O9B)?
Almirall, S.A reported trailing-twelve-month revenue of about €1.2B (latest available figure, as of Sep 24, 2026).
Does Almirall, S.A pay a dividend?
Almirall, S.A currently shows a dividend yield of about 1.83% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Almirall, S.A (0O9B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Almirall, S.A it is €8.65 per share (as of Sep 24, 2026), against a price of €10.20. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Almirall, S.A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0O9B trades above its calculated fair value: price €10.20, fair value €8.65, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0O9B?
No. The price is what the market pays today (€10.20); the fair value is what the company's own numbers justify (€8.65). For Almirall, S.A the two are €1.55 per share apart. That gap is exactly why we show both numbers side by side.
How much is Almirall, S.A worth?
The market values Almirall, S.A at about €1.8B (market capitalisation, as of Sep 24, 2026). Per share that is €10.20; our models calculate a fair value of €8.65 per share.
What do the bullish and bearish scenarios say about 0O9B?
Our models span a range for Almirall, S.A: cautious scenario €6.40, base €8.65, optimistic €10.91 per share (as of Sep 24, 2026, price €10.20). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0O9B from its 52-week high?
Almirall, S.A trades at €10.20, about 25% below its 52-week high of €13.66 and 2% above the low of €10.02 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €8.65 is for.
Which stocks are comparable to Almirall, S.A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Almirall, S.A stock attractive at the current price?
The data as of Sep 24, 2026: price €10.20, calculated fair value €8.65 (−15%), Quality Score 59/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0O9B calculated?
We run Almirall, S.A through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €8.65, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Almirall, S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Almirall, S.A (0O9B)?
The closing price on Oct 2, 2026 was €10.20. Our model-based fair value is €8.65, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Almirall, S.A right now?
Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Almirall, S.A
How large is the market capitalisation of Almirall, S.A (0O9B)?
The market capitalisation of Almirall, S.A is €1.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Almirall, S.A (0O9B)?
The price-to-sales ratio of Almirall, S.A is 1.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Almirall, S.A (0O9B)?
Earnings per share at Almirall, S.A are €−0.2790. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Almirall, S.A (0O9B)?
The dividend yield of Almirall, S.A is 1.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Almirall, S.A (0O9B)?
The net margin of Almirall, S.A is 9.2% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Almirall, S.A (0O9B)?
The return on equity (ROE) of Almirall, S.A is 4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Almirall, S.A (0O9B)?
On an EBIT basis the return on assets of Almirall, S.A is 0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Almirall, S.A (0O9B)?
The operating margin of Almirall, S.A is 13.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Almirall, S.A (0O9B)?
Revenue at Almirall, S.A is growing +13.0% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Almirall, S.A (0O9B)?
Earnings per share at Almirall, S.A are growing +138% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
